Regencell Bioscience Ownership
| RGC Stock | USD 5.35 0.25 4.90% |
Shares in Circulation | First Issued 2002-06-30 | Previous Quarter 13 M | Current Value 13 M | Avarage Shares Outstanding 142.5 M | Quarterly Volatility 161.8 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Regencell |
Regencell Stock Ownership Analysis
About 89.0% of the company outstanding shares are owned by corporate insiders. The book value of Regencell Bioscience was at this time reported as 0.92. The company has Price/Earnings To Growth (PEG) ratio of 2.15. Regencell Bioscience recorded a loss per share of 0.45. The entity last dividend was issued on the 1st of December 2017. Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine bioscience company. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong. Regencell Bioscience operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 13 people. To find out more about Regencell Bioscience Holdings contact Amy Miles at 852 2155 0823 or learn more at https://www.regencellbioscience.com.Besides selling stocks to institutional investors, Regencell Bioscience also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Regencell Bioscience's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Regencell Bioscience's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Regencell Bioscience Quarterly Liabilities And Stockholders Equity |
|
About 89.0% of Regencell Bioscience Holdings are currently held by insiders. Unlike Regencell Bioscience's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Regencell Bioscience's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Regencell Bioscience's insider trades
Regencell Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Regencell Bioscience is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Regencell Bioscience Holdings backward and forwards among themselves. Regencell Bioscience's institutional investor refers to the entity that pools money to purchase Regencell Bioscience's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Group Ag | 2023-12-31 | 16.1 K | Blackrock Inc | 2023-12-31 | 238 | Qube Research & Technologies | 2023-12-31 | 13.0 | Morgan Stanley - Brokerage Accounts | 2023-12-31 | 0.0 | Tower Research Capital Llc | 2023-12-31 | 0.0 |
Regencell Bioscience Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Regencell Bioscience insiders, such as employees or executives, is commonly permitted as long as it does not rely on Regencell Bioscience's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Regencell Bioscience insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Amy Miles over a month ago Disposition of 33006 shares by Amy Miles of Regencell Bioscience at 21.58 subject to Rule 16b-3 | ||
Peter Brandow over a month ago Disposition of 1265 shares by Peter Brandow of Regencell Bioscience at 22.87 subject to Rule 16b-3 |
Regencell Bioscience Corporate Filings
6K | 2nd of January 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 27th of October 2023 Other Reports | ViewVerify |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Regencell Bioscience in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Regencell Bioscience's short interest history, or implied volatility extrapolated from Regencell Bioscience options trading.
Currently Active Assets on Macroaxis
When determining whether Regencell Bioscience offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regencell Bioscience's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regencell Bioscience Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regencell Bioscience Holdings Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regencell Bioscience Holdings. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Regencell Bioscience information on this page should be used as a complementary analysis to other Regencell Bioscience's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Complementary Tools for Regencell Stock analysis
When running Regencell Bioscience's price analysis, check to measure Regencell Bioscience's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regencell Bioscience is operating at the current time. Most of Regencell Bioscience's value examination focuses on studying past and present price action to predict the probability of Regencell Bioscience's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regencell Bioscience's price. Additionally, you may evaluate how the addition of Regencell Bioscience to your portfolios can decrease your overall portfolio volatility.
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |
Is Regencell Bioscience's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regencell Bioscience. If investors know Regencell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regencell Bioscience listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.45) | Return On Assets (0.26) | Return On Equity (0.42) |
The market value of Regencell Bioscience is measured differently than its book value, which is the value of Regencell that is recorded on the company's balance sheet. Investors also form their own opinion of Regencell Bioscience's value that differs from its market value or its book value, called intrinsic value, which is Regencell Bioscience's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regencell Bioscience's market value can be influenced by many factors that don't directly affect Regencell Bioscience's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regencell Bioscience's value and its price as these two are different measures arrived at by different means. Investors typically determine if Regencell Bioscience is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regencell Bioscience's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.